Aardvark Therapeutics Bolsters Leadership Ahead of Key Clinical Readouts
Event summary
- Aardvark Therapeutics appoints Derrick C. Li as Chief Business Officer and expands Nelson Sun’s role to include Chief Operating Officer, effective February 9, 2026.
- Li will lead business development strategy, including financing, licensing, and partnerships.
- Sun will oversee operations alongside his existing CFO role as the company advances ARD-101 through Phase 3 trials for Prader-Willi Syndrome.
- Topline Phase 3 data for ARD-101 expected in Q3 2026, with Phase 2 trials ongoing for ARD-201 in obesity.
The big picture
Aardvark Therapeutics is fortifying its leadership team as it approaches critical clinical milestones for its lead asset, ARD-101. The appointments of Li and Sun’s expanded role signal a focus on scaling operations and business development ahead of potential regulatory and commercialization decisions. The moves come as the biopharmaceutical sector increasingly prioritizes operational agility to navigate the complexities of rare disease and metabolic disorder treatments.
What we're watching
- Clinical Execution
- How the Phase 3 topline data for ARD-101 in Q3 2026 will impact Aardvark’s valuation and strategic partnerships.
- Business Development
- Whether Derrick Li’s business development strategy can secure licensing deals or financing to support Aardvark’s growth.
- Operational Scaling
- The pace at which Nelson Sun can integrate COO responsibilities with his existing CFO role amid clinical trial progress.
Related topics